Lifeward (NASDAQ:LFWD) Stock Price Down 2.7% – What’s Next?

Lifeward Ltd. (NASDAQ:LFWD) traded down 2.7% during trading on Wednesday . The stock traded as low as $1.02 and last traded at $1.07. 121,585 shares were traded during trading, a decline of 83% from the average session volume of 695,758 shares. The stock had previously closed at $1.10.

Analysts Set New Price Targets

LFWD has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of Lifeward in a research note on Tuesday, March 11th. Lake Street Capital decreased their price objective on shares of Lifeward from $4.50 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th.

Lifeward Trading Down 2.7%

The firm has a market capitalization of $11.78 million, a PE ratio of -0.35 and a beta of 0.16. The firm has a 50-day moving average of $1.31 and a two-hundred day moving average of $1.57.

Lifeward (NASDAQ:LFWD) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.13). The company had revenue of $5.03 million during the quarter, compared to analysts’ expectations of $5.84 million. Lifeward had a negative net margin of 108.21% and a negative return on equity of 101.96%. Equities research analysts expect that Lifeward Ltd. will post -1.78 earnings per share for the current fiscal year.

About Lifeward

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.